HSPC Gene Therapy for Inherited Eye Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for hereditary eye diseases, such as ocular cystinosis, are limited to symptom management without cures or preventative measures, and existing treatments are costly and burdensome, with significant side effects and quality of life impacts for patients.
Innovation Solution
The method involves introducing a functional human protein or gene associated with the disease, specifically cystinosin (CTNS), into hematopoietic stem and progenitor cells (HSPCs) using vectors like lentiviral or AAV vectors, and transplanting these cells into the subject, either systemically or locally into the eye, to produce the missing protein and reduce cystine accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptom management therapies are used for hereditary eye diseases, then patients can manage symptoms temporarily, but the diseases progress leading to blindness and organ failure without cure
Solution Approach 1:
The patent applies preliminary action by introducing functional genes into HSPCs before the disease causes irreversible damage. The gene-modified HSPCs are prepared in advance and then transplanted to produce therapeutic proteins that prevent disease progression, rather than treating symptoms after damage occurs.
Solution Approach 2:
The patent uses HSPCs as an intermediary carrier to deliver functional genes to target tissues. The HSPCs serve as mobile factories that produce and transport therapeutic proteins (like cystinosin) to multiple organs including the eye, kidney, and other affected tissues, replacing the need for direct organ-specific gene delivery.
2Adaptability or versatility
If systemic gene therapy is applied to treat multi-organ diseases like cystinosis, then multiple organs can be treated simultaneously, but the complexity of delivering genes to all affected tissues increases
Solution Approach 1:
The patent achieves universality by using HSPCs as a multi-functional delivery system. These cells can home to and treat multiple different organs (eye, kidney, liver, etc.) simultaneously through a single transplantation procedure, eliminating the need for separate delivery systems for each organ.
Solution Approach 2:
The gene-modified HSPCs exhibit self-service behavior by autonomously navigating to and engrafting in multiple target organs throughout the body. The cells self-organize and distribute therapeutic proteins to where they are needed without external guidance, simplifying the delivery system.
Data Source
AI summary
Provided herein are methods for treating an inherited eye disease or disorder through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject's eyes in need of treatment. Also provided are vectors containing the nucleic acid molecule.